Home Company Technology Research & Development Partnerships Clinical Contact
News
> Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?
> Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors
> Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma
> PPARgamma as a new therapeutic target in inflammatory bowel diseases
> The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD)

Bringing novel ideas into innovative medicines


Intestinal Biotech Development is partnering with searchers, pharmaceutical, food ingredients companies in the long run to bring the fertile ideas into marketed medicines, food ingredients, from in-silico modelization to preclinical and clinical studies.

A large progress has been observed for around a decade in the treatment of the digestive tract diseases including the inflammatory bowel diseases. New strategies, advanced technology therapies, have been established. But some unmet medical needs still remain nowadays . More ambitious and demanding requirements for the patient’s benefits, new therapeutic targets, innovative medicines are still the goal for every searcher all around the world.

On the other hand, nutrition and gut health are major concerns for a large population. Some food ingredients appear to have interesting properties to improve the intestinal comfort in the functional disturbances including pain. These fields need to be explored with specific ingredients.





All logos and trademarks in this plateform are property of their respective owner.
The comments are property of their posters, all the rest © 2008 by ibd-biotech.com.
Plateforme version: Alpha 1.0 -© 2008 - Pyramidale-communication.com - 3c01®